Persistent urticarial rash in a newborn

Allergy and Asthma Proceedings ◽

10.2500/aap.2021.42.200103 ◽

2021 ◽

Author(s):

Iwona Dziewa ◽

Timothy Hahn ◽

Neeti Bhardwaj

Keyword(s):

Differential Diagnosis ◽

Inflammatory Markers ◽

Initial Evaluation ◽

Response To Treatment ◽

Therapeutic Trial ◽

Age Group ◽

Diagnostic Modality ◽

Urticarial Rash

We presented the case of a 1-month-old girl with diffuse urticarial-like rash since birth. The initial evaluation showed elevated inflammatory markers. The response to treatment helped to narrow the diagnosis. In this case, we explored the differential diagnosis of rashes in this age group and the role of a therapeutic trial of medication as a diagnostic modality.

Download Full-text

The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept

Clinical and Experimental Dermatology ◽

10.1111/j.1365-2230.2011.04131.x ◽

2011 ◽

Vol 36 (8) ◽

pp. 845-850 ◽

Cited By ~ 38

Author(s):

A. Kanelleas ◽

C. Liapi ◽

A. Katoulis ◽

P. Stavropoulos ◽

G. Avgerinou ◽

...

Keyword(s):

Disease Severity ◽

Inflammatory Markers ◽

Response To Treatment

Download Full-text

Efficacy of interleukin-1 blockade in Schnitzler’s syndrome without detectable monoclonal gammopathy: a case-based review

Clinical Rheumatology ◽

10.1007/s10067-020-05501-w ◽

2020 ◽

Author(s):

Riccardo Bixio ◽

Maurizio Rossini ◽

Alessandro Giollo

Keyword(s):

Complete Remission ◽

Inflammatory Markers ◽

Monoclonal Gammopathy ◽

Interleukin 1 ◽

Autoinflammatory Disorder ◽

Urticarial Rash ◽

Schnitzler’S Syndrome ◽

Inflammatory Drugs ◽

Case Based

Abstract Schnitzler’s syndrome (SchS) is a rare autoinflammatory disorder characterized by urticarial rash and monoclonal gammopathy which is currently regarded as IL-1 mediated disease. We present the case of a 21-year-old woman presenting with urticarial rash, arthralgias, and elevated inflammatory markers. She has been suffering these symptoms for 2 years and was treated with antihistamines, omalizumab, steroids, and non-steroidal anti-inflammatory drugs (NSAIDs) without success. After an extensive diagnostic workout, we suspected SchS even without monoclonal gammopathy, and started Anakinra 100 mg daily with a dramatic response and achieving complete remission after 48 h of the beginning of the treatment, so we decided to confirm SchS diagnosis. We performed a search of the literature and found seven more cases of patients diagnosed with SchS without monoclonal gammopathy at the presentation. Five were treated with IL-1 blocking therapies and all achieved remission. We, therefore, prompt the possible role of IL-1 blockade therapy remission as support in diagnosing SchS without monoclonal gammopathy.

Download Full-text